MCID: FML037
MIFTS: 51

Female Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Female Breast Cancer

MalaCards integrated aliases for Female Breast Cancer:

Name: Female Breast Cancer 12 15
Female Breast Carcinoma 12 15 70
Malignant Neoplasm of Female Breast 70
Mammary Carcinoma of Female Breast 12
Carcinoma of Female Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050671 DOID:7843
NCIt 50 C2918
UMLS 70 C0007104 C0235653

Summaries for Female Breast Cancer

Disease Ontology : 12 A breast carcinoma that is manifested in the female breast.

MalaCards based summary : Female Breast Cancer, also known as female breast carcinoma, is related to tubular adenocarcinoma and progesterone-receptor positive breast cancer. An important gene associated with Female Breast Cancer is PGR (Progesterone Receptor), and among its related pathways/superpathways are DNA Double-Strand Break Repair and PI3K-Akt signaling pathway. The drugs Anastrozole and Toremifene have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and prostate, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Female Breast Cancer

Diseases related to Female Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 335)
# Related Disease Score Top Affiliating Genes
1 tubular adenocarcinoma 30.3 PGR ESR1 ERBB2
2 progesterone-receptor positive breast cancer 30.1 PGR ESR1 ERBB2
3 apnea, obstructive sleep 30.0 TNF LEP IGF1
4 cervix carcinoma 29.9 TP53 PGR ESR1 ERBB2
5 androgenic alopecia 29.9 KLK3 IGF1 AR
6 sexual disorder 29.9 KLK3 IGF1 AR
7 mulchandani-bhoj-conlin syndrome 29.9 PGR ESR1 ERBB2 BRCA1
8 mammary paget's disease 29.8 PGR ESR1 ERBB2 AR
9 sleep apnea 29.8 TNF LEP IGF1
10 insulin-like growth factor i 29.8 LEP IGF1 ESR1
11 glucose intolerance 29.8 TNF LEP IGF1 ESR1
12 fanconi anemia, complementation group j 29.6 PALB2 BRCA2 BRCA1
13 skin melanoma 29.6 TP53 TNF ERBB2 BRCA1 ATM
14 gynecomastia 29.6 PGR LEP KLK3 ESR1 ERBB2 AR
15 in situ carcinoma 29.5 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
16 adenoid cystic carcinoma 29.5 TP53 PGR ERBB2 BRCA1 ATM
17 adenocarcinoma 29.4 TP53 KLK3 ERBB2 BRCA2 BRCA1
18 infertility 29.4 PGR LEP ESR1 CYP1A1 AR
19 liver cirrhosis 29.4 TP53 TNF LEP IGF1 CYP1A1 ALDH2
20 breast-ovarian cancer, familial 2 29.3 BRCA2 BRCA1
21 breast fibroadenoma 29.3 TP53 PGR ESR1 ERBB2 BRCA1 AR
22 body mass index quantitative trait locus 11 29.2 TNF LEP IGF1 ESR1 BRCA2 AR
23 type 2 diabetes mellitus 29.2 TP53 TNF LEP IGF1 ESR1 CYP1A1
24 hereditary breast ovarian cancer syndrome 29.2 TP53 PALB2 ERBB2 BRCA2 BRCA1 ATM
25 breast carcinoma in situ 29.2 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
26 ductal carcinoma in situ 29.1 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
27 estrogen-receptor positive breast cancer 28.9 TP53 TOX3 PGR ESR1 ERBB2 BRCA1
28 breast ductal carcinoma 28.9 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
29 sporadic breast cancer 28.6 XRCC1 TP53 PGR PALB2 ESR1 ERBB2
30 endometrial cancer 28.5 TP53 PGR KLK3 IGF1 ESR1 ERBB2
31 breast disease 28.2 XRCC1 TP53 TNF PGR KLK3 IGF1
32 skin carcinoma 27.7 XRCC1 TP53 TNF PGR KLK3 ESR1
33 breast cancer 27.7 XRCC1 TP53 TOX3 TOP2A TNF PGR
34 lung cancer 27.4 XRCC1 TP53 TOP2A TNF IGF1 ESR1
35 prostate cancer 27.2 XRCC1 TP53 TOP2A TNF PGR KLK3
36 female breast nipple and areola cancer 11.1
37 female breast central part cancer 11.1
38 female breast lower-outer quadrant cancer 11.1
39 female breast upper-inner quadrant cancer 11.1
40 female breast lower-inner quadrant cancer 11.1
41 female breast axillary tail cancer 11.1
42 female breast upper-outer quadrant cancer 11.1
43 sister chromatid exchange, frequency of 10.4 XRCC1 ALDH2
44 hypogonadism, male 10.4 LEP KLK3
45 laryngeal mucoepidermoid carcinoma 10.4 KLK3 ERBB2
46 prostate adenoid cystic carcinoma 10.4 KLK3 AR
47 prostate leiomyoma 10.4 KLK3 AR
48 gastric papillary adenocarcinoma 10.4 TP53 ERBB2
49 xeroderma pigmentosum-cockayne syndrome complex 10.4 ERCC4 ERCC2
50 tuberculous epididymitis 10.3 TNF KLK3

Comorbidity relations with Female Breast Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Breast Fibroadenosis
Deficiency Anemia Fat Necrosis of Breast
Hypertension, Essential Hypothyroidism
Mastitis Microglandular Adenosis
Neutropenia

Graphical network of the top 20 diseases related to Female Breast Cancer:



Diseases related to Female Breast Cancer

Symptoms & Phenotypes for Female Breast Cancer

GenomeRNAi Phenotypes related to Female Breast Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.96 BRCA1 BRCA2 ERCC4 PALB2 TOP2A XRCC1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.96 ATM BRCA1 BRCA2 ERCC4 PALB2 TOP2A
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.96 ATM BRCA1 BRCA2 ERCC2 ERCC4 TP53
4 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 ATM TP53
5 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 ATM BRCA1 PALB2 TNF TOP2A TP53
6 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.83 ATM BRCA1 BRCA2 PALB2 TOP2A TP53

MGI Mouse Phenotypes related to Female Breast Cancer:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.5 ALDH2 AR ATM BRCA1 BRCA2 ERBB2
2 cellular MP:0005384 10.49 ALDH2 AR ATM BRCA1 BRCA2 ERBB2
3 growth/size/body region MP:0005378 10.48 ALDH2 AR ATM BRCA1 BRCA2 CYP1A1
4 homeostasis/metabolism MP:0005376 10.48 ALDH2 AR ATM BRCA1 BRCA2 CYP1A1
5 cardiovascular system MP:0005385 10.44 ALDH2 AR ATM BRCA1 ERBB2 ESR1
6 mortality/aging MP:0010768 10.41 ALDH2 AR ATM BRCA1 BRCA2 CYP1A1
7 endocrine/exocrine gland MP:0005379 10.4 ALDH2 AR ATM BRCA1 BRCA2 CYP1A1
8 embryo MP:0005380 10.38 AR ATM BRCA1 BRCA2 ERBB2 ESR1
9 hematopoietic system MP:0005397 10.38 ALDH2 AR ATM BRCA1 BRCA2 CYP1A1
10 immune system MP:0005387 10.36 ALDH2 AR ATM BRCA1 BRCA2 CYP1A1
11 integument MP:0010771 10.34 ALDH2 AR ATM BRCA1 BRCA2 ERBB2
12 limbs/digits/tail MP:0005371 10.29 ALDH2 AR BRCA1 BRCA2 ERBB2 ESR1
13 adipose tissue MP:0005375 10.26 AR ATM BRCA1 ERCC2 ESR1 IGF1
14 neoplasm MP:0002006 10.24 ALDH2 AR ATM BRCA1 BRCA2 ERBB2
15 digestive/alimentary MP:0005381 10.18 AR BRCA1 BRCA2 ERBB2 ESR1 LEP
16 nervous system MP:0003631 10.17 ALDH2 AR ATM BRCA1 BRCA2 ERBB2
17 muscle MP:0005369 10.14 ALDH2 AR BRCA1 ERBB2 ESR1 IGF1
18 liver/biliary system MP:0005370 10.06 ALDH2 AR CYP1A1 ERCC4 ESR1 LEP
19 normal MP:0002873 10 AR BRCA1 BRCA2 CYP1A1 ERBB2 ESR1
20 reproductive system MP:0005389 9.77 ALDH2 AR ATM BRCA1 BRCA2 ERBB2
21 pigmentation MP:0001186 9.63 ALDH2 AR BRCA1 ERCC2 LEP TP53
22 skeleton MP:0005390 9.44 ALDH2 AR BRCA1 BRCA2 ERBB2 ERCC2

Drugs & Therapeutics for Female Breast Cancer

Drugs for Female Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
2
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
3
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
5 Estrogen Antagonists Phase 4
6 Estrogens Phase 4
7 Estrogen Receptor Antagonists Phase 4
8 Estrogen Receptor Modulators Phase 4
9 Anesthetics Phase 4
10 Hypnotics and Sedatives Phase 4
11 Anesthetics, Intravenous Phase 4
12 Anesthetics, Inhalation Phase 4
13 Anesthetics, General Phase 4
14 Platelet Aggregation Inhibitors Phase 4
15
Epirubicin Approved Phase 2 56420-45-2 41867
16
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
17
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
18
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
19
Darbepoetin alfa Approved, Investigational Phase 2 209810-58-2, 11096-26-7
20
Tamoxifen Approved Phase 2 10540-29-1 2733526
21
Donepezil Approved Phase 2 120014-06-4 3152
22
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 5330286 11431660
23
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
24
Polyestradiol phosphate Approved Phase 2 28014-46-2
25
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
26 Tubulin Modulators Phase 2
27 Antibiotics, Antitubercular Phase 2
28 Immunosuppressive Agents Phase 2
29 Immunologic Factors Phase 2
30 Antimitotic Agents Phase 2
31 Antirheumatic Agents Phase 2
32 Alkylating Agents Phase 2
33 Anti-Bacterial Agents Phase 2
34 Antimetabolites Phase 2
35 Aromatase Inhibitors Phase 2
36 Neurotransmitter Agents Phase 2
37 Cholinergic Agents Phase 2
38 Epoetin alfa Phase 2 113427-24-0
39 Hematinics Phase 2
40 Nootropic Agents Phase 2
41 Cholinesterase Inhibitors Phase 2
42 Protein Kinase Inhibitors Phase 2
43 Estradiol 3-benzoate Phase 2
44 Estradiol 17 beta-cypionate Phase 2
45
Sodium citrate Approved, Investigational 68-04-2
46
Fentanyl Approved, Illicit, Investigational, Vet_approved 437-38-7 3345
47
Atracurium Approved, Experimental, Investigational 64228-79-1 47319
48
Thiopental Approved, Vet_approved 76-75-5 3000715
49
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 5743
50
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Evaluation of Adjuvant Endocrine Therapy for Operable ER-beta Positive, ER-alpha/PR Negative, Her-2 Negative Breast Cancer Patients Unknown status NCT02089854 Phase 4 Toremifene; Anastrozole
2 Does Anesthesia Technique Affect the Presence of Circulating Tumor Cells in Primary Breast Carcinoma? A Randomised Controlled Trial. Completed NCT02005770 Phase 4 Sevoflurane;Propofol
3 Differential Gene Regulation During Neoadjuvant Therapy Trial of Epirubicin/Cyclophosphamide (EC) vs Docetaxel/Capecitabine (DX) Regimens in Patients With Large ER-positive and ER-negative Breast Cancers: A Randomized Phase II Trial. Completed NCT01869192 Phase 2 Epirubicin;Cyclophosphamide;Docetaxel;Capecitabine
4 Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer Completed NCT01671319 Phase 2 docetaxel + cyclophosphamide + pegfilgrastim
5 An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Female Breast Cancer Patients Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy Completed NCT00120692 Phase 2 Darbepoetin Alfa;Recombinant Human Erythropoietin
6 A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor Completed NCT03518138 Phase 2 Q-122;Placebo
7 A Feasibility Study of Donepezil in Female Breast Cancer Survivors With Self-Reported Cognitive Dysfunction Following Chemotherapy Completed NCT01466270 Phase 2 donepezil hydrochloride;Placebo
8 Pilot Trial of Anastrozole and Palbociclib as First-Line Therapy and as Maintenance Therapy After First Line Chemotherapy in Hormone Receptor Positive, HER2-Negative Postmenopausal Metastatic Breast Cancer Recruiting NCT02942355 Phase 2 anastrozole;Palbociclib
9 An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery Active, not recruiting NCT03113825 Phase 2 AVB-620
10 An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy Terminated NCT02540330 Phase 2 Fulvestrant
11 A Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer Terminated NCT01083641 Phase 2 Estradiol
12 Effect of Yoga on Life Quality and Immunity in Breast Cancer Patients After Operation and or Chemotherapy Unknown status NCT02243163
13 Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens Unknown status NCT02480933
14 A Prospective, Randomized, Controlled Trial to Compare the Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serumserum Biomarkers and on PBMCs in Patients Undergoing Breast Cancer Resection Surgery Unknown status NCT03005860 2,6-Diisopropylphenol;Fluoromethyl hexafluoroisopropyl ether;Fentanyl Citrate;Atracurium Besylate
15 Evaluating Female Sexual Dysfunction in Breast Cancer Patients After Mastectomy Unknown status NCT03153631
16 Clinical Application of Nocebo Research: Optimizing Expectations of Breast Cancer Patients to Prevent Nocebo Side Effects and Decrease of Quality of Life During Adjuvant Endocrine Therapy (DFG, NE 1635/2-1) Unknown status NCT01741883
17 Clinical Cohort of Individual Expectations, Side Effects, Quality of Life and Adherence in Postoperative Women With Estrogen Receptor Positive Breast Cancer During Endocrine Therapy Unknown status NCT02088710
18 Genetic Counseling for Breast Cancer Survivors (GC for BC) Completed NCT02451735
19 Text for Health: Integrating Technology and Health Communication to Improve Health Outcomes (Part 2 of 2) Completed NCT04290585
20 Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini Completed NCT01643148
21 Metabolic Syndrome and Female Breast Cancer: a Case-control Study in Southern Brazil Completed NCT02282592
22 Trends of Mastectomy and Breast-Conserving Surgery and Related Factors in Female Breast Cancer Patients Treated at King Abdulaziz University Hospital, Jeddah, Saudi Arabia, 2009-2017 Completed NCT03762642
23 The Effects of Auricular Acupressure on Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients: A Pilot Randomized Controlled Trial Completed NCT02403037 Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)
24 The Treatment For Recurrent Female Breast Cancer After Initial Endocrine Therapy Among Taiwanese Population Completed NCT02924584
25 Randomized Clinical Trial Comparing Two Adjuvant Radiotherapy Hypo Fractionation Schedules In The Treatment of Post Mastectomy Breast Cancer Patients Recruiting NCT04550910
26 Acupuncture for Joint Symptoms in Patients With Breast Cancer: A Randomised Controlled Trial Recruiting NCT03836872
27 A Phase III, Randomized, Single Blind, Attention Controlled, Multi-center Study of the Effects of a Rehabilitation Intervention on Participation Restrictions of Female Breast Cancer Survivors Recruiting NCT03915548
28 Effects of a Traditional Chinese Exercise Program- Tai Chi on Symptom Cluster of Fatigue-sleep Disturbance-depression in Female Breast Cancer Patients: a Preliminary Randomized Controlled Trial Recruiting NCT04190342
29 Monocentric, Randomized Clinical Trial About the Effect of Yoga Practice on QOL, Physiological Distress and Fatigue, on Patients Affected by Breast Cancer Undergoing Adjuvant Radiotherapy Active, not recruiting NCT04775290
30 Autologous Fat Transfer: Introduction of a Full Breast Reconstructive Method Not yet recruiting NCT04261829
31 Synbiotic Supplementation to Reduce Anxiety Symptoms in Female Breast Cancer Survivors Not yet recruiting NCT04784182
32 Breast Cancer in Young Women: Is it Different? Suspended NCT01320488
33 The Process and Outcomes of Treatment Decision-Making Communication Between Oncologists and Newly Diagnosed Female Breast-Cancer Patients Terminated NCT00891969
34 The Efficacy of Reduced-exertion High-intensity Interval Training for Improving Health and Well-being in Newly Diagnosed Female Breast Cancer Patients Withdrawn NCT03176888

Search NIH Clinical Center for Female Breast Cancer

Genetic Tests for Female Breast Cancer

Anatomical Context for Female Breast Cancer

MalaCards organs/tissues related to Female Breast Cancer:

40
Breast, Lymph Node, Prostate, Brain, Skin, Colon, Cervix

Publications for Female Breast Cancer

Articles related to Female Breast Cancer:

(show top 50) (show all 2517)
# Title Authors PMID Year
1
A deep-learning semantic segmentation approach to fully automated MRI-based left-ventricular deformation analysis in cardiotoxicity. 61
33571634 2021
2
Risk of Cancer in Long-Term Levothyroxine Users: Retrospective Population-based Study. 61
33793038 2021
3
Validation of a deep-learning semantic segmentation approach to fully automate MRI-based left-ventricular deformation analysis in cardiotoxicity. 61
33571002 2021
4
Breast Cancer Mortality Rates Have Stopped Declining in U.S. Women Younger than 40 Years. 61
33560186 2021
5
Male Breast Cancer in Australia. 61
31957255 2021
6
Prospective study of hair recovery after (neo)adjuvant chemotherapy with scalp cooling in Japanese breast cancer patients. 61
33797582 2021
7
Occupational exposure to solar ultraviolet B radiation and risk of subtypes of breast cancer in Danish women. 61
33531359 2021
8
Mental health-related quality of life is associated with diet quality among survivors of breast cancer. 61
32844314 2021
9
The effects of dyadic coping and marital satisfaction on posttraumatic growth among breast cancer couples. 61
33709185 2021
10
Mammography use and breast cancer incidence among older U.S. women. 61
33666831 2021
11
Epidemiological characteristics and forecasting incidence for patients with breast cancer in Shantou, Southern China: 2006-2017. 61
33724693 2021
12
Characteristics of healthy behavior in Mexican women who survived breast cancer. 61
33780875 2021
13
The effect of bariatric surgery on breast cancer incidence and characteristics: A meta-analysis and systematic review. 61
33771341 2021
14
An updated review of epidemiology, risk factors, and management of male breast cancer. 61
33721121 2021
15
Female breast cancer treatment and survival in South Australia: Results from linked health data. 61
33779005 2021
16
Correlation Between Financial Toxicity, Quality of Life, and Patient Satisfaction in an Insured Population of Breast Cancer Surgical Patients: A Single-Institution Retrospective Study. 61
33316424 2021
17
Feasibility of Remote Occupational Therapy Services via Telemedicine in a Breast Cancer Recovery Program. 61
33657345 2021
18
Association of Living in Urban Food Deserts with Mortality from Breast and Colorectal Cancer. 61
32844294 2021
19
Cancer incidence estimation from mortality data: a validation study within a population-based cancer registry. 61
33757540 2021
20
Clinicopathological correlates, oncological impact, and validation of Oncotype DX™ in a European Tertiary Referral Centre. 61
33709552 2021
21
Atypical vascular proliferations of the neck. 61
32757107 2021
22
Does the choice of care pathways matter in timely breast cancer care in Sri Lanka? 61
33348244 2021
23
Socio-Economic Position, Cancer Incidence and Stage at Diagnosis: A Nationwide Cohort Study in Belgium. 61
33668089 2021
24
Implementation of a Brief Screening Tool to Identify Needs of Breast Cancer Survivors. 61
32807644 2021
25
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 61
33538338 2021
26
Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study. 61
33526812 2021
27
Modelling the number of avoidable new cancer cases in France attributable to alcohol consumption by following official recommendations: a simulation study. 61
33565659 2021
28
Risk of two common glandular cell-type cancers (breast and colorectal cancers) in Chinese occupational chefs: a nationwide ecological study in Taiwan. 61
33646334 2021
29
A review on age-related cancer risks in PTEN hamartoma tumor syndrome. 61
33140411 2021
30
Mammography use in relation to comorbidities and functional limitations among older breast cancer survivors. 61
32720225 2021
31
Evidence of Epstein-Barr Virus in Female Breast Cancer. 61
33748013 2021
32
The Effect of Metformin on Survival Outcomes of Non-Metastatic Breast Cancer Patients with Type 2 Diabetes. 61
33639681 2021
33
Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients. 61
33113089 2021
34
Female breast cancer in New South Wales, Australia, by country of birth: implications for health-service delivery. 61
33596880 2021
35
Examination of incidence, mortality and disability-adjusted life years and risk factors of breast cancer in 49 Asian countries, 1990-2019: estimates from Global Burden of Disease Study 2019. 61
33621341 2021
36
Chemical carcinogen-induced rat mammary carcinogenesis is a potential model of p21-activated kinase positive female breast cancer. 61
33346690 2021
37
Elastosis in ERα-positive male breast cancer. 61
32929565 2021
38
To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis? 61
33104958 2021
39
Relationship between particulate matter exposure and female breast cancer incidence and mortality: a systematic review and meta-analysis. 61
32914230 2021
40
The role of space in obstructing clinical sexual health education: A qualitative study on breast cancer patients' perspectives on barriers to expressing sexual concerns. 61
33565165 2021
41
Occupational Heat Exposure and Breast Cancer Risk in the MCC-Spain Study. 61
33268491 2021
42
Breast-Conserving Therapy is Associated with Improved Survival Compared with Mastectomy for Early-Stage Breast Cancer: A Propensity Score Matched Comparison Using the National Cancer Database. 61
32661849 2021
43
Potential role of significant GATA3 mutation in male breast cancer responding to endocrine therapy: A case report. 61
33433431 2021
44
Combined A20 and tripartite motif-containing 44 as poor prognostic factors for breast cancer patients of the Japanese population. 61
33159706 2021
45
Comparison of the performance of four staging systems in determining the prognosis of breast cancer among women undergoing neoadjuvant chemotherapy. 61
33417086 2021
46
BRCA1 and BRCA2 truncating mutations and variants of unknown significance in Egyptian female breast cancer patients. 61
33278427 2021
47
The association of continuity of care and risk of mortality in breast cancer patients with cardiometabolic comorbidities. 61
33459213 2021
48
Geographical and socioeconomic inequalities in female breast cancer incidence and mortality in Iran: A Bayesian spatial analysis of registry data. 61
33730079 2021
49
Breast Cancer Population Screening Program Results in Early Detection and Reduced Treatment and Health Care Costs for Medicaid. 61
31592983 2021
50
Development and validation of a Tai chi intervention protocol for managing the fatigue-sleep disturbance-depression symptom cluster in female breast cancer patients. 61
33259909 2021

Variations for Female Breast Cancer

Expression for Female Breast Cancer

Search GEO for disease gene expression data for Female Breast Cancer.

Pathways for Female Breast Cancer

Pathways related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.1 XRCC1 TP53 PALB2 ERCC4 ERCC2 BRCA2
2
Show member pathways
12.95 TP53 TNF IGF1 ERBB2 BRCA1 ATM
3
Show member pathways
12.81 TP53 KLK3 IGF1 ERBB2 BRCA2 AR
4 12.7 TP53 KLK3 IGF1 ESR1 ERBB2 BRCA2
5
Show member pathways
12.58 TP53 PGR IGF1 ESR1 ERBB2 BRCA2
6
Show member pathways
12.47 TP53 IGF1 ESR1 ERBB2 BRCA2 BRCA1
7
Show member pathways
12.32 TP53 IGF1 BRCA1 ATM
8
Show member pathways
12.25 TP53 KLK3 IGF1 ERBB2 AR
9 12.22 TP53 TNF IGF1 ESR1 ERBB2
10
Show member pathways
12.17 PALB2 ERCC4 BRCA2 BRCA1 ATM
11
Show member pathways
12.08 PALB2 BRCA2 BRCA1 ATM
12 12.03 XRCC1 TP53 TOP2A ERCC4 ERCC2 BRCA2
13
Show member pathways
11.88 XRCC1 TP53 IGF1 ESR1 ERCC4 ERCC2
14 11.83 PALB2 ERCC4 BRCA2 BRCA1
15 11.82 TP53 ESR1 BRCA2 BRCA1 ATM AR
16
Show member pathways
11.77 TP53 BRCA1 ATM
17
Show member pathways
11.77 TP53 BRCA2 BRCA1 ATM
18 11.68 XRCC1 BRCA1 ATM
19 11.58 TP53 ERBB2 BRCA1 ATM
20 11.57 KLK3 BRCA1 AR
21 11.52 TP53 TOP2A ERBB2 BRCA1 ATM
22 11.49 TNF ESR1 CYP1A1
23 11.46 TP53 BRCA1 ATM
24 11.45 TNF IGF1 AR
25 11.43 TP53 BRCA1 ATM
26
Show member pathways
11.38 TP53 TOP2A ERCC2
27
Show member pathways
11.37 KLK3 ESR1 BRCA1 AR
28 11.34 XRCC1 ESR1 BRCA2
29 11.26 TP53 BRCA1 ATM
30 11.21 TP53 BRCA1 ATM
31 10.98 TP53 BRCA1 ATM

GO Terms for Female Breast Cancer

Cellular components related to Female Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.13 XRCC1 TP53 TOX3 TOP2A PGR PALB2
2 chromosome, telomeric region GO:0000781 9.62 XRCC1 ERCC4 BRCA2 ATM
3 protein-containing complex GO:0032991 9.5 TP53 TOP2A KLK3 ESR1 BRCA2 BRCA1
4 nucleoplasm GO:0005654 9.44 XRCC1 TP53 TOX3 TOP2A PGR PALB2
5 ERCC4-ERCC1 complex GO:0070522 9.16 XRCC1 ERCC4

Biological processes related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.27 TP53 TOX3 TNF PGR ESR1 ERBB2
2 positive regulation of transcription, DNA-templated GO:0045893 10.09 TP53 TNF IGF1 ESR1 BRCA2 BRCA1
3 negative regulation of gene expression GO:0010629 10 TP53 TNF PGR IGF1 ESR1
4 positive regulation of gene expression GO:0010628 9.98 TP53 TNF IGF1 ERBB2 BRCA1 ATM
5 in utero embryonic development GO:0001701 9.97 TP53 PALB2 ERCC2 AR
6 positive regulation of protein kinase B signaling GO:0051897 9.96 TNF LEP ESR1 ERBB2
7 regulation of apoptotic process GO:0042981 9.96 TP53 TOX3 ESR1 BRCA1 ATM
8 transcription initiation from RNA polymerase II promoter GO:0006367 9.93 PGR ESR1 ERCC2 AR
9 cell proliferation GO:0008283 9.91 IGF1 ERCC2 CYP1A1 BRCA2
10 response to hypoxia GO:0001666 9.89 XRCC1 LEP ERCC2 CYP1A1 ATM
11 positive regulation of MAPK cascade GO:0043410 9.87 LEP IGF1 ERBB2 AR
12 DNA repair GO:0006281 9.87 XRCC1 PALB2 ERCC4 ERCC2 BRCA2 BRCA1
13 transcription-coupled nucleotide-excision repair GO:0006283 9.86 XRCC1 ERCC4 ERCC2
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 TNF LEP IGF1
15 positive regulation of transcription by RNA polymerase II GO:0045944 9.85 TP53 TOX3 TOP2A TNF PGR IGF1
16 double-strand break repair GO:0006302 9.84 TP53 BRCA2 BRCA1
17 positive regulation of neuron apoptotic process GO:0043525 9.83 TP53 TNF ATM
18 double-strand break repair via nonhomologous end joining GO:0006303 9.83 XRCC1 ERCC4 BRCA1 ATM
19 positive regulation of cell adhesion GO:0045785 9.81 TNF ERBB2 ATM
20 response to UV GO:0009411 9.8 TP53 ERCC4 ERCC2
21 somitogenesis GO:0001756 9.79 TP53 PALB2 ATM
22 embryonic organ development GO:0048568 9.78 TP53 PALB2 ERCC2
23 determination of adult lifespan GO:0008340 9.71 TP53 LEP ATM
24 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.71 TNF BRCA2 BRCA1 ATM
25 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.69 TP53 ESR1
26 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.69 TP53 BRCA2 BRCA1
27 response to salt stress GO:0009651 9.68 TP53 TNF
28 negative regulation of lipid storage GO:0010888 9.68 TNF LEP
29 female meiotic nuclear division GO:0007143 9.67 TOP2A ATM
30 nucleotide-excision repair GO:0006289 9.67 TP53 ERCC4 ERCC2 BRCA2
31 bone mineralization involved in bone maturation GO:0035630 9.66 LEP IGF1
32 embryonic cleavage GO:0040016 9.65 TOP2A ERCC2
33 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.65 TP53 TNF ESR1
34 multicellular organism growth GO:0035264 9.65 TP53 PALB2 ERCC2 ATM AR
35 ovulation from ovarian follicle GO:0001542 9.64 PGR LEP
36 intracellular steroid hormone receptor signaling pathway GO:0030518 9.63 PGR ESR1 AR
37 chordate embryonic development GO:0043009 9.62 BRCA2 BRCA1
38 cellular response to DNA damage stimulus GO:0006974 9.61 XRCC1 TP53 TOP2A PALB2 ERCC4 ERCC2
39 negative regulation of protection from non-homologous end joining at telomere GO:1905765 9.59 XRCC1 ERCC4
40 telomeric DNA-containing double minutes formation GO:0061819 9.58 XRCC1 ERCC4
41 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.58 PGR AR
42 double-strand break repair via homologous recombination GO:0000724 9.1 XRCC1 PALB2 ERCC4 BRCA2 BRCA1 ATM

Molecular functions related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.53 XRCC1 TP53 TOX3 TOP2A TNF PGR
2 identical protein binding GO:0042802 9.97 TP53 TNF PGR ESR1 ERCC4 ERBB2
3 chromatin binding GO:0003682 9.89 TP53 TOX3 TOP2A ESR1 AR
4 transcription regulatory region sequence-specific DNA binding GO:0000976 9.83 TP53 TNF BRCA1 AR
5 DNA binding GO:0003677 9.77 TP53 TOX3 TOP2A PGR PALB2 LEP
6 ATPase binding GO:0051117 9.71 PGR ESR1 AR
7 protein N-terminus binding GO:0047485 9.67 TP53 ERCC4 ERCC2 ATM
8 protein C-terminus binding GO:0008022 9.65 TOP2A ERCC4 ERCC2 ERBB2 BRCA2
9 nuclear receptor activity GO:0004879 9.63 PGR ESR1 AR
10 steroid binding GO:0005496 9.58 PGR ESR1 AR
11 TFIID-class transcription factor complex binding GO:0001094 9.51 TP53 ERCC4
12 RNA polymerase II transcription coactivator binding GO:0001225 9.48 PGR AR
13 damaged DNA binding GO:0003684 9.46 XRCC1 ERCC4 ERCC2 BRCA1
14 3' overhang single-stranded DNA endodeoxyribonuclease activity GO:1990599 9.43 XRCC1 ERCC4
15 enzyme binding GO:0019899 9.23 XRCC1 TP53 TOP2A PGR ESR1 CYP1A1

Sources for Female Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....